Edit Entry | Edit CV

Surachai Supattapone, MD, PhD

Title(s)
Professor of Biochemistry and Cell Biology
Professor of Medicine

Department(s)
Biochemistry and Cell Biology
Medicine

Education
Johns Hopkins University School of Medicine, Ph.D. 1992
Johns Hopkins University School of Medicine, M.D. 1992, Oxford University D.Phil. 1991

Programs
Molecular and Cellular Biology Graduate Programs
Molecular Pathogenesis Program
Neuroscience Center at Dartmouth

Websites
http://dms.dartmouth.edu/supattapone/
http://dms.dartmouth.edu/ncd/
http://dms.dartmouth.edu/mcb/faculty/supattapone.php
http://www.dartmouth.edu/~m2p2/colleagues/faculty.html#supattapone

Contact Information

Dartmouth Medical School
74 College Street
Vail Building Room 311
Hanover NH 03755

Office: 603-646-5212
Phone: 603-646-5213
Email: supattapone@dartmouth.edu


Professional Interests

Prion Diseases
Neurodegeneration
Protein Misfolding
Genome-wide CRISPR screens

Biography

Surachai joined the Dartmouth faculty in 2001, and has enjoyed teaching in the Year One Metabolism and Scientific Basis of Medicine courses for medical students, as well as the Core Course for Molecular and Cellular Biology graduate students. He has also greatly enjoyed having the opportunity to mentor students conducting laboratory research projects on the pathogenesis of prion disease. Surachai has also served as the Chair for the Molecular and Cellular Biology (MCB) Graduate Program, the director for the Clinical Translational Science Masters Program, a director for the Cellular and Molecular Basis of Disease course, and member of the Medical Education Committee and the Committee for Student Performance and Conduct. He has also served as a standing member of two NIH study sections. He has won teaching awards at Geisel and at the University of California at San Francisco, and been elected as a Fellow to both the American Society for Microbiology (ASM) and the American Association for the Advancement of Science (AAAS).


Selected Publications

 

Generation of Infectious Prions Amenable to Site-specific Click Chemistry.
Campbell RG, Iseler JN, Schwind AM, Supattapone S
bioRxiv. 2026 Apr 10; pii: 2026.04.08.717205. doi: 10.64898/2026.04.08.717205. Epub 2026 Apr 10.
PMID: 41993530

Energy Flux Regulates Cell Death Induced by California Serogroup Orthobunyaviruses.
Francomacaro LM, Matey H, Beauchemin KS, Evans AB, Supattapone S
bioRxiv. 2026 Mar 14; pii: 2026.03.13.711679. doi: 10.64898/2026.03.13.711679. Epub 2026 Mar 14.
PMID: 41958990

Mutant knock-in mice display enhanced susceptibility to pure prion protein fibrils.
Walsh DJ, Standke H, Kraus A, Watts JC, Supattapone S
J Gen Virol. 2026 Feb;107(2) doi: 10.1099/jgv.0.002219.
PMID: 41642644

Genome-wide screens identify core regulators of cell surface prion protein expression.
Beauchemin KS, Supattapone S
Sci Rep. 2026 Jan 21;16(1):5895. doi: 10.1038/s41598-026-37137-2. Epub 2026 Jan 21.
PMID: 41565761

Oligosaccharyltransferase (OST) complex inhibition effectively treats rodent and human prions.
Beauchemin KS, Kun J, Groveman B, Williams K, Salerno F, Francomacaro LM, Robison P, Haigh CL, Supattapone S
PLoS Pathog. 2026 Jan;22(1):e1013867. doi: 10.1371/journal.ppat.1013867. Epub 2026 Jan 12.
PMID: 41525337

Genome-Wide Screens Identify Core Regulators of Cell Surface Prion Protein Expression.
Beauchemin KS, Supattapone S
bioRxiv. 2025 Dec 9; pii: 2025.12.07.692843. doi: 10.64898/2025.12.07.692843. Epub 2025 Dec 9.
PMID: 41427295

Convergent generation of atypical prions in knockin mouse models of genetic prion disease.
Mehra S, Bourkas ME, Kaczmarczyk L, Stuart E, Arshad H, Griffin JK, Frost KL, Walsh DJ, Supattapone S, Booth SA, Jackson WS, Watts JC
J Clin Invest. 2024 Aug 1;134(15) doi: 10.1172/JCI176344. Epub 2024 Aug 1.
PMID: 39087478

Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease.
Walsh DJ, Rees JR, Mehra S, Bourkas MEC, Kaczmarczyk L, Stuart E, Jackson WS, Watts JC, Supattapone S
PLoS Pathog. 2024 Apr;20(4):e1012087. doi: 10.1371/journal.ppat.1012087. Epub 2024 Apr 1.
PMID: 38557815

Correction: Emergence of Prions Selectively Resistant to Combination Drug Therapy.
Burke CM, Mark KMK, Kun J, Beauchemin KS, Supattapone S
PLoS Pathog. 2024 Jan;20(1):e1011919. doi: 10.1371/journal.ppat.1011919. Epub 2024 Jan 8.
PMID: 38190351

Anti-prion drugs do not improve survival in knock-in models of inherited prion disease.
Walsh DJ, Rees JR, Mehra S, Bourkas MEC, Kaczmarczyk L, Stuart E, Jackson WS, Watts JC, Supattapone S
bioRxiv. 2023 Sep 29; pii: 2023.09.28.559951. doi: 10.1101/2023.09.28.559951. Epub 2023 Sep 29.
PMID: 37808761

View more publications on PubMed